BRPI0509497A - seqüência de polipeptìdeos na modulação do efeito imunosupressor de proteìnas virais - Google Patents

seqüência de polipeptìdeos na modulação do efeito imunosupressor de proteìnas virais

Info

Publication number
BRPI0509497A
BRPI0509497A BRPI0509497-6A BRPI0509497A BRPI0509497A BR PI0509497 A BRPI0509497 A BR PI0509497A BR PI0509497 A BRPI0509497 A BR PI0509497A BR PI0509497 A BRPI0509497 A BR PI0509497A
Authority
BR
Brazil
Prior art keywords
modulating
polypeptide sequence
viral proteins
immunosuppressive effect
protein
Prior art date
Application number
BRPI0509497-6A
Other languages
English (en)
Inventor
Martial Renard
Marianne Mangeney
Therry Heidmann
Original Assignee
Roussy Inst Gustave
Centre Nat Rech Scient
Univ Paris Sud Xi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Centre Nat Rech Scient, Univ Paris Sud Xi filed Critical Roussy Inst Gustave
Publication of BRPI0509497A publication Critical patent/BRPI0509497A/pt
Publication of BRPI0509497B1 publication Critical patent/BRPI0509497B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SEQUêNCIA DE POLIPEPTìDEOS ENVOLVIDA NA MODULAçãO DO EFEITO IMUNOSUPRESSOR DE PROTEìNAS VIRAIS A presente invenção se refere a um polipeptídeo tendo uma seqüência de 7 a 20 resíduos de aminoácido, que é capaz de modular as propriedades imunosupressoras de uma proteína viral, ou um fragmento desta, contra o hospedeiro no qual ela é expressa (seqüência de imunosupressão-modulatória) quando substitui a seqüência homóloga de referida proteína viral ou fragmento, referido polipeptídeo compreendendo a seqüência de amino ácido de consenso seguinte mínimo: X1 Y9 Y10 Y11 CY12 X2(subscritos) no qual X1 e X2 são selecionados para impactarem nas referidas propriedades imunosupressora, e Y9 a Y12 representam resíduos de aminoácido variáveis.
BRPI0509497-6A 2004-03-30 2005-03-30 Seqüência de polipeptídeos envolvida na modulação do efeito imunosupressor de proteínas virais BRPI0509497B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290838.4 2004-03-30
EP04290838 2004-03-30
PCT/EP2005/003339 WO2005095442A1 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Publications (2)

Publication Number Publication Date
BRPI0509497A true BRPI0509497A (pt) 2007-09-11
BRPI0509497B1 BRPI0509497B1 (pt) 2022-07-19

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509497-6A BRPI0509497B1 (pt) 2004-03-30 2005-03-30 Seqüência de polipeptídeos envolvida na modulação do efeito imunosupressor de proteínas virais

Country Status (14)

Country Link
US (2) US8178657B2 (pt)
EP (1) EP1732585B1 (pt)
JP (1) JP5060284B2 (pt)
CN (1) CN1961001B (pt)
AT (1) ATE472334T1 (pt)
AU (1) AU2005229411B2 (pt)
BR (1) BRPI0509497B1 (pt)
CA (1) CA2561376C (pt)
DE (1) DE602005022056D1 (pt)
ES (1) ES2347445T3 (pt)
IL (1) IL178205A (pt)
MX (1) MXPA06011272A (pt)
WO (1) WO2005095442A1 (pt)
ZA (1) ZA200608178B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
JP5624994B2 (ja) 2009-01-09 2014-11-12 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 新たなレセプター結合性リガンド、生物学的対象の細胞の検出におけるその使用
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
US20130260394A1 (en) * 2010-09-17 2013-10-03 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
US8895027B2 (en) * 2011-07-20 2014-11-25 Merial Limited Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
CA2856180C (en) 2011-12-07 2022-09-06 Viroxis S.A.S. Mutated lentiviral env proteins and their use as drugs
EP3004143B1 (en) 2013-06-07 2019-10-23 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
EP3309178A4 (en) * 2015-06-11 2019-05-08 Keio University FUSION PROTEIN OR CONJUGATED PROTEIN, CARRIER FOR INTRA-CELLULAR DELIVERY, PARTICLE PEPTIDE, CELL MEMBRANE PERMEATION AMPLIFIER, DNA AND VECTOR
JP7037486B2 (ja) * 2015-10-01 2022-03-16 エイムヴィオン・アクティエセルスカブ 医薬としてのヒト由来免疫抑制タンパク質およびペプチドの使用
DK3676285T3 (da) 2017-09-01 2026-01-19 Inprother Aps Vaccine til anvendelse i profylakse og/eller behandling af en sygdom
AU2019343045A1 (en) 2018-09-18 2021-05-13 Vnv Newco Inc. ARC-based capsids and uses thereof
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
CA3204201A1 (en) 2021-01-13 2022-07-21 Thierry Heidmann Measles-hiv or measles-htlv vaccine
WO2024218400A1 (en) 2023-04-21 2024-10-24 Inprother Aps Improved expression of surface-displayed antigens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
ES2179854T3 (es) 1988-12-13 2003-02-01 Harvard College Materiales aislados de felv prototipos para uso en modelos de enfermedades y vacunas.
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
JP2003512844A (ja) * 1999-10-28 2003-04-08 ユニヴェルシテ・ドゥ・ジュネーブ 多発性硬化症関連スーパー抗原
AU2002230758A1 (en) * 2000-12-11 2002-06-24 Tufts University Treatment and prevention of EBV infection and EBV-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
US8178657B2 (en) 2012-05-15
WO2005095442A8 (en) 2006-11-02
JP2008506357A (ja) 2008-03-06
DE602005022056D1 (de) 2010-08-12
CA2561376C (en) 2016-06-21
IL178205A0 (en) 2006-12-31
ZA200608178B (en) 2008-10-29
AU2005229411A1 (en) 2005-10-13
US8597657B2 (en) 2013-12-03
EP1732585B1 (en) 2010-06-30
CA2561376A1 (en) 2005-10-13
WO2005095442A1 (en) 2005-10-13
CN1961001B (zh) 2012-09-05
BRPI0509497B1 (pt) 2022-07-19
JP5060284B2 (ja) 2012-10-31
EP1732585A1 (en) 2006-12-20
MXPA06011272A (es) 2007-04-17
AU2005229411B2 (en) 2010-11-18
ATE472334T1 (de) 2010-07-15
IL178205A (en) 2015-05-31
ES2347445T3 (es) 2010-10-29
US20080008683A1 (en) 2008-01-10
US20120189647A1 (en) 2012-07-26
CN1961001A (zh) 2007-05-09

Similar Documents

Publication Publication Date Title
BRPI0509497A (pt) seqüência de polipeptìdeos na modulação do efeito imunosupressor de proteìnas virais
PT1685243E (pt) Linhas celulares aviárias imortalizadas para a produção de vírus
CY1117162T1 (el) Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
BR112016015512A2 (pt) proteínas quiméricas de fator viii e suas utilizações
WO2005032487A3 (en) Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
ATE543506T1 (de) Methode zur stabilisierung von proteinen
BR112012031329A2 (pt) proteínas de fusão diméricas vstm3 e composições e métodos relacionados
MX2013015323A (es) Polipeptidos de fusion de serpina y metodos de uso de los mismos.
EA201170635A1 (ru) Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
ATE466868T1 (de) Zusammensetzungen und verfahren zur trennung von fusionsproteinen
MX2022014162A (es) Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
MX2007007586A (es) Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.
ATE463512T1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
JOP20240256A1 (ar) بروتينات اندماج hmpv مُستقرة في صورة ما قبل الإندماج
WO2007053188A3 (en) Production of multivalent virus like particles
ATE478965T1 (de) Lentivirusvektoren und deren verwendung
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
DE60117998D1 (de) Mutierte furin polypeptide, welche verbesserte eigenschaften aufweisen
PH12022553417A1 (en) Stabilized corona virus spike protein fusion proteins
DE60330680D1 (de) Transferrin-fusionsproteinbibliotheken
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
ATE450546T1 (de) Impfstoffe mit ornithobakterium rhinotracheale- untereinheit

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: INSTITUT GUSTAVE ROUSSY (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; UNIVERSITE PARIS-SACLAY (FR)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.